A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection  by Knapp, Susanne et al.
O
t
w
p
.
0
c
H
h
g
C
s
p
K
f
(
B
A
SIC
A
N
D
TR
A
N
SLA
TIO
N
A
L
LIV
ER
GASTROENTEROLOGY 2011;141:320–325BASIC AND TRANSLATIONAL—LIVER
A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals
From Spontaneous Resolvers of HCV Infection
SUSANNE KNAPP,* USAMA WARSHOW,‡ K. M. ALEXANDER HO,* DOHA HEGAZY,‡ ANN–MARGARET LITTLE,§
ANDREW FOWELL, GRAEME ALEXANDER,¶ MARK THURSZ,* MATTHEW CRAMP,‡ and SALIM I. KHAKOO*
*Department of Hepatology, Division of Medicine, Imperial College London; ‡Hepatology Research Group, Peninsula Medical School and South West Liver Unit,
§ Derriford Hospital, Plymouth; Laboratory of Histocompatibility and Immunogenetics, Gartnavel General Hospital, Glasgow; Department of Hepatology, Southampton
General Hospital, Southampton; and ¶Department of Medicine, University of Cambridge, Cambridge, United Kingdom
p
s
c
c
c
i
t
o
i
l
i
i
w
t
K
pBACKGROUND & AIMS: Polymorphisms in the inter-
leukin-28B (IL28B) gene are associated with outcomes from
infection with hepatitis C virus (HCV). However, the role of
these polymorphisms in protecting injection drug users who
are at high risk for HCV infection but do not have detectable
antibodies against HCV or HCV RNA (exposed uninfected)
has not been demonstrated. We investigated whether these
individuals have the IL28B genotype rs12979860-CC, which
protects some individuals against HCV infection. METH-
DS: Seventy-four exposed uninfected individuals, 89 spon-
aneous resolvers, and 234 chronically infected individuals
ere genotyped to determine single nucleotide polymor-
hisms at IL28B.rs12979860.RESULTS: Exposed, uninfected
individuals had a significantly lower frequency of the pro-
tective genotype (rs12979860-CC) than anti-HCV-positive
spontaneous resolvers (41.9% vs 69.7%, respectively; P 
0005; odds ratio [OR], 0.31; 95% confidence interval [CI]:
.16–0.60) but a similar frequency to patients who were
hronically infected (41.9% vs 43.6%, respectively; P  ns).
owever, exposed, uninfected individuals had a significantly
igher frequency of homozygosity for killer cell immuno-
lobulin-like receptor 2DL3:group 1 HLA-C (KIR2DL3:HLA-
1) than those with chronic infection (31.1% vs 13.3%, re-
pectively; P  .0008; OR, 2.95; 95% CI: 1.59–5.49). For
atients who spontaneously resolved infection, IL28B and
IR:HLA protected, independently, against chronic HCV in-
ection, based on logistic regression and synergy analyses
synergy factor, 1.3; 95% CI: 0.37–4.75; P synergy  .6).
CONCLUSIONS: IL28B and KIR2DL3:HLA-C1 are inde-
pendently associated with spontaneous resolution of
viremia following HCV exposure. Resistance to HCV
infection in exposed uninfected cases is associated with
homozygosity for KIR2DL3:HLA-C1 but not the single
nucleotide polymorphism IL28B.rs12979860. Uninfected
individuals are therefore a distinct population from pa-
tients who spontaneously resolve HCV infection. Dis-
tinct, nonsynergistic innate immune mechanisms can
determine outcomes of HCV exposure.
Keywords: Killer Cell Immunoglobulin-Like Receptor; Ge-
netics; Liver Disease; Protective Mechanisms.Hepatitis C virus (HCV) is a common chronic viralinfection with only a minority of individuals ex-
osed to HCV infection being able to resolve infection
pontaneously. Clearance of HCV is dependent on a suc-
essful immune response, which likely involves T cells, B
ells, dendritic cells, and also natural killer cells (NK)
ells.1 Consistent with a broad immune response being
mportant, polymorphisms of both the innate and adap-
ive immune system are associated with spontaneous res-
lution of HCV infection.2
Recent work has highlighted that polymorphisms in
the Interleukin-28B (IL28B) gene (interferon [IFN]-3) are
strongly associated with both spontaneous resolution of
HCV infection and also resolution of infection with pegy-
lated interferon and ribavirin.2–7 Similarly, the killer cell
mmunoglobulin-like receptors (KIR) and their human
eukocyte antigen class I ligands have also been implicated
n spontaneous and treatment-induced resolution of HCV
nfection.8–11 In particular, KIR2DL3 and its ligands, the
group 1 HLA-C allotypes (HLA-C1), are protective against
chronic HCV infection and, hence, are beneficial factors in
outcome following exposure to HCV.
A minority of long-term injection drug users (IDU)
demonstrate apparent resistance to HCV infection and
remain seronegative and aviremic despite likely repeated
exposure to HCV through the sharing of drug injection
equipment. These exposed but uninfected (EU) IDU cases
have been shown to have detectable HCV-specific T-cell
responses, indicating their exposure to HCV infection.12,13
They also have increased NK cell activity.14 Consistent
ith this, we have recently shown that, similar to conven-
ional spontaneous resolvers (SR), the combination of
IR2DL3 and HLA-C1 is also over-represented in the ex-
osed seronegative aviremic population.10 Additionally,
Abbreviations used in this paper: EU, exposed but uninfected; HCV,
hepatitis C virus; Hencore, Hepatitis C European Network for Coopera-
tive Research collaboration; HLA, human leukocyte antigen; HLA-C1,
group 1 HLA-C allotype; IDU, injection drug users; IFN, interferon; KIR,
killer cell immunoglobulin-like receptor; NK, natural killer cells; SNP,
single nucleotide polymorphism; SR, spontaneous resolvers.
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July 2011 IL28B IN EXPOSED UNINFECTED INDIVIDUALS 321both groups of protected individuals have an increased
frequency of a functional interleukin-12 (IL-12) polymor-
phism as compared with chronically infected individu-
als.15,16
To date, the protective effect of IL28B in this subgroup
of individuals has not been investigated. Furthermore, it
is not well understood whether protective polymorphisms
in the immune system work together to increase protec-
tion against chronic HCV infection or whether these com-
ponents of the innate immune system act independently.
The aim of this study was therefore to determine whether
the EU population have a protective IL28B genotype and
to determine how protective IL28B and KIR:HLA-C poly-
orphisms may interact to influence the outcome of HCV
nfection in untreated individuals.
Patients and Methods
Patients
Three hundred ninety-seven patients (74 exposed
uninfected, 89 SR, and 234 chronically infected patients)
were studied for the distribution of the IL28B.rs12979860
single nucleotide polymorphism (SNP), KIR2DL2/3 and
HLA-C genotypes. All patients gave informed consent with
approval by the relevant ethics committees as previously
described.8,10,17 Patients were excluded if they were human
mmunodeficiency virus positive or hepatitis B virus sur-
ace antigen positive. The patients are classified into the
ollowing 3 cohorts: (1) exposed uninfected (EU) cohort,
2) spontaneous resolving (SR), and (3) chronically in-
ected individuals.
Exposed uninfected cohort. Seventy-four individ-
als were recruited from Dartmoor Prison, needle ex-
hanges, community drug services, and hostels in Plym-
uth, United Kingdom. All these individuals were of
aucasian ethnicity. They had an extensive history of past
r present injection drug use. This group was defined as
eing both HCV antibody (third generation enzyme
inked immunosorbent assay, Abbott IMx, Abbott Diag-
ostics, Maidenhead, Berkshire, United Kingdom) and
CV RNA (Amplicor, Roche Diagnostics, Pleasanton, CA)
egative on at least 2 occasions, 3–6 months apart with
ubsequent testing on an approximate 6 monthly basis to
nsure that this profile remained unchanged. Forty-two of
hese cases had been genotyped previously for KIR2DL2/3
nd HLA-C.10 Detailed information about drug injecting
behavior was ascertained by means of a structured ques-
tionnaire, and the median duration of intravenous drug
use was 8.62  6.05 years (range, 0.3–24) with a median
number of injections of 4927 (range, 36–41,620).10 Their
median age was 28 years, and 64 (79%) were male.
SRs. Individuals were classified in this group if they
had detectable anti-HCV by second-generation enzyme-
linked immunosorbent assay (Abbott IMx; Abbott Diag-
nostics, Maidenhead, Berkshire, United Kingdom) and no
detectable HCV viremia by Quantiplex HCV RNA 2.0
assay (Chiron, Emeryville, CA) or HCV COBAS Amplicor
system (Roche Diagnostics, Pleasanton, CA) on at least 2occasions 6 months apart. They were recruited between
1995 and 1998 as part of the Hepatitis C European Net-
work for Cooperative Research (Hencore) collabora-
tion17,18 and between 1999 and 2005 from Addenbrookes
ospital, Cambridge, United Kingdom, and Southamp-
on General Hospital, United Kingdom.8 Eighty-seven
98%) were Caucasian, 59 (66%) were male, and their
edian age was 36 years. Forty-four had been genotyped
reviously for KIR2DL2/3 and HLA-C.8
Chronically infected individuals. These individual
were all persistently anti-HCV and HCV RNA positive, by
second-generation enzyme-linked immunosorbent assay
(Abbott IMx) and HCV COBAS Amplicor system (Roche
Diagnostics, Pleasanton, CA), respectively. They were re-
cruited from the general hepatology clinic at Southamp-
ton General Hospital, United Kingdom, between 2003
and 2007. Two hundred seventeen (93%) were of Cauca-
sian origin, with a median age of 45 years, and 138 (59%)
were male.10 All had been genotyped previously for
IR2DL2/3 and HLA-C.8
Genotyping
Genomic DNA was extracted from peripheral
blood lymphocytes using a salt precipitation method,17
Nucleon DNA extraction kit (Tepnel Lifesciences, Man-
chester, United Kingdom) or the QIAamp blood kit (Qia-
gen, Crawley, United Kingdom). All samples were typed
for the rs12979860 SNP using a real-time polymerase
chain technique incorporating Sybr Green (Qiagen Quan-
tiTect SYBR; Qiagen). The primers used were as follows:
5=-GCTTATCGCATACGGCTAGGC-3= (forward com-
mon), 5=-GCAATTCAACCCTGGTTCG-3= (C- allele spe-
cific reverse) and 5=-GCAATTCAACCCTGGTTCA-3= (T-
allele specific reverse). Reactions were performed on a
5700 Perkin Elmer (Cambridge, United Kingdom) ma-
chine using 96-well plates and 10–100 ng genomic DNA
with 0.5 mol/L of each primer in a reaction mix of total
olume 20 L. The thermal cycling protocol consisted of
n initial denaturation step of 95°C for 10 minutes,
ollowed by 40 two-step amplification cycles of 95°C for
0 seconds and 58°C for 20 seconds.
KIR2DL2/3 genotyping was performed on the Hencore
ohort and the 32 additional exposed uninfected individ-
als by polymerase chain reaction using sequence specific
rimers as previously described.19 HLA typing was per-
formed on the Hencore and EU cohorts as described
elsewhere.20 HLA types that were not resolved by sequenc-
ng or that gave unusual results were also tested by se-
uence-specific oligonucleotide probe typing using com-
ercial kits (RELI SSO; Dynal, Wirral, United Kingdom).
ther cohorts had previously been typed for KIR2DL2/3
nd HLA-C.8,10
Statistical Analysis
GraphPad Prism 5 software (GraphPad, Inc, La
Jolla, CA) was used to calculate 2-tailed P values and odds
ratios (OR) from 2  2 contingency tables by Fisher exact
test. Logistic regression analysis was performed using
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322 KNAPP ET AL GASTROENTEROLOGY Vol. 141, No. 1SPSS statistical software version 17 (SPSS, Inc, Chicago,
IL) with the ENTER function. Synergy between IL28B and
KIR:HLA was calculated using the method of Cortina-
Borja et al.21
Results
IL28B Polymorphism Distinguishes Exposed
Uninfected Individuals From Anti-HCV-
Positive Spontaneous Resolvers
The frequency of the protective CC genotype at the
SNP rs12979860-CC in the 74 EU individuals was signifi-
antly lower than in the 89 SR (41.9% vs 69.7%, respec-
ively, P  .0005; OR, 0.31; 95% confidence interval [CI]:
.16–0.60) but was similar to that found in the 234
ndividuals with chronic HCV infection (41.9% vs 43.6%,
espectively) (Table 1). Consistent with previous work, the
requency of the IL28B.rs12979860-CC genotype was sig-
ificantly higher in the spontaneous resolving population
ompared with those with chronic infection (69.7% vs
3.6%, respectively, P  .0001; OR, 2.97, 95% CI: 1.76–
.00). We also found that CT heterozygosity was more
revalent in the EU as compared with the SR population
43.2% vs 24.7%, respectively, P  .019; OR, 2.32, 95% CI:
1.19–4.52), and this genotype was lower in the SR popu-
lation as compared with the chronically infected individ-
uals (24.7% vs 48.7%, respectively, P  .0001; OR, 0.35,
5% CI: 0.20–0.60). Additionally, we found that there was
trend toward an increase in TT homozygosity in the EU
opulation as compared with both SR (14.9% vs 5.6%,
espectively, P  .06; OR, 2.93, 95% CI: 0.97–8.87) and
lso chronically infected individuals (14.9% vs 7.7%, re-
pectively, P  .07; OR, 2.09, 95% CI: 0.94–4.67). This is
espite the overall T allele frequency being similar be-
ween EU and chronically infected individuals (36.5% vs
2.1%, respectively) (Supplementary Tables 1 and 2).
hese observations remained similar if only Caucasian
ndividuals were considered (Supplementary Table 3).
hus, the rs12979860 polymorphism distinguishes the EU
opulation from those that spontaneously resolve HCV
Table 1. Frequency of the IL28B.rs12979860-CC, CT, and TT
Resolvers, and 234 Chronically Infected HCV Patient
rs12979860
Genotype EU, n (%) SR, n (%) Chr, n (%)
CC 31 (41.9) 62 (69.7) 102 (43.6) P  .0
95% C
CT 32 (43.2) 22 (24.7) 114 (48.7) P  .0
95% C
TT 11 (14.9) 5 (5.6) 18 (7.7) P  .0
95% C
NOTE. Two-tailed P values were calculated for 2  2 contingency table
5% CI, 95% confidence interval; Chr, chronically infected HCV patiennfection. 0IL28B and KIR:HLA Define Distinct
Populations of HCV Protected Individuals
Although IL28B.rs12979860-CC was not associated
with protection in the EU cohort, these individuals are
genetically distinct from those with chronic HCV because
homozygosity for KIR2DL3:HLA-C1 is over-represented in
this population as compared with those with chronic
HCV (31.1% vs 13.3%, respectively, P  .0008; OR, 2.95,
5% CI: 1.59–5.49) (Supplementary Table 4). KIR2DL3:
HLA-C1 was found at a similar frequency to the anti-HCV-
positive SR population (31.1% vs 29.2%, respectively, P 
s), as we have previously shown in a subgroup of these
ndividuals.10 We therefore hypothesized that KIR and
L28B genes might define distinct groups of individuals
ho are protected against chronic HCV infection using
ifferent genetic pathways. To study the interrelationship
f these genes on the outcome of hepatitis C, we com-
ared the frequency of IL28B.rs12979860-CC in individuals
ith and without the protective KIR2DL3:HLA-C1 ho-
ozygous genotype from all 3 cohorts (EU, SR, and
hronic).
In individuals who had spontaneously resolved infec-
ion and were not KIR2DL3:HLA-C1 homozygous, the fre-
uency of the rs12979860-CC genotype was significantly
igher compared with chronically infected individuals
68.3% [SR] vs 41.9% [chronic], P  .0003; OR, 2.98, 95%
I: 1.64–5.43, Table 2). The effect was similar in individ-
als who were KIR2DL3:HLA-C1 homozygous, but this did
ot reach statistical significance (73.1% vs 54.8%, respec-
ively, P  .18; OR, 2.23, 95% CI: 0.73–6.84), most likely
ecause of the small sample size. Likewise, the protective
ffect of KIR2DL3:HLA-C1 homozygosity was similar in in-
ividuals with the rs12979860-CC genotype (30.6% [SR] vs
6.7% [chronic], P .051; OR, 2.21, 95% CI: 1.04–4.68) and
lso without the rs12979860-CC genotype (25.9% SR vs 10.6%
hronic, P  .055; OR, 2.95, 95% CI: 1.06–8.21). Similarly,
e found an under-representation of rs12979860-CC in EU as
ompared with SR in both the KIR2DL3:HLA-C1 homozy-
ous and nonhomozygous subgroups (P  .046; OR, 0.28,
5% CI: 0.09–0.94 and P  .0046; OR, 0.33, 95% CI: 0.15–
notype in 74 Exposed Uninfected, 89 Spontaneous
vs SR EU vs Chr SR vs Chr
5 (Pc  .002)
 0.31
.160.60
P  .1 P  .0001 (Pc  .0002)
OR  2.97
95% CI: 1.765.00
(Pc  .057)
 2.32
.194.52
P  .1 P  .0001 (Pc  .0002)
OR  0.35
95% CI: 0.200.60
Pc  .1)
 2.93
.978.87
P  .07 (Pc  .1)
OR  2.09
95% CI: 0.944.67
P  .1
sing Fisher exact test, and the Bonferroni correction was applied (Pc).
OR, odds ratio.Ge
s
EU
00
OR
I: 0
19
OR
I: 1
6 (
OR
I: 0
s u.70, respectively, Table 2).
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July 2011 IL28B IN EXPOSED UNINFECTED INDIVIDUALS 323In univariate analysis, the frequency of the combination
of rs12979860-CC and KIR2DL3:HLA-C1 homozygosity in
the SR group was 21% as compared with only 7.3% in the
chronically infected group (P  .0007; OR, 3.47, 95% CI:
1.71–7.03). However, it is not clear whether these 2 pro-
tective genetic factors are acting synergistically or inde-
pendently. To determine this, we performed multivariate
logistic regression analysis using 3 variables: rs12979860-
CCKIR2DL3:HLA-C1 homozygosity; rs12979860-CC with
or without KIR2DL3:HLA-C1 homozygosity; and KIR2DL3:
HLA-C1 homozygosity with or without rs12979860-CC.
This analysis tests whether the combination of the 2 factors
provides additional benefit above that due to each factor
individually. This demonstrated that the rs12979860-CC ge-
notype and KIR2DL3:HLA-C1 homozygosity are protective in
isolation (P  .001 and P  .04, respectively), and having
both rs12979860-CC and KIR2DL3:HLA-C1 homozygosity to-
gether does not confer any additional protection (P  .1)
(Table 3). Additionally, we applied a recently described test to
evaluate the synergistic effects of genetic factors.21 This
method is based on logistic regression analysis and compares
the ORs of protection among the different groups. It deter-
mines whether the observed OR for 2 factors considered in
combination is greater than that of having both protective
factors assuming independent effects of each factor. In this
case, 4 groupings were tested: (1) rs12979860-CC positive, not
KIR2DL3:HLA-C1 homozygous; (2) KIR2DL3:HLA-C1 ho-
mozygous, rs12979860-CC negative; (3) rs12979860-CC posi-
ive and KIR2DL3:HLA-C1 homozygous; and (4) neither
s12979860-CC positive nor KIR2DL3:HLA-C1 homozygous.
sing this test, we confirmed the absence of synergy
etween the 2 protective factors in the SR population
synergy factor  1.3 [95% CI: 0.37–4.75], Psynergy  .6).
ecause the synergy factor can uncover unexpected
ynergies, we determined this statistic for the EU pop-
lation in comparison with the chronically infected
Table 2. Effect of rs12979860-CC Homozygosity in 89 Spont
Uninfected Individuals With and Without the KIR2DL3
Comparison (n) rs12979
KIR2DL3:C1 homozygous SR (26) vs Chr (31) 19 (73.1
EU (23) vs SR (26) 10 (43.5
ot KIR2DL3:C1 homozygous SR (63) vs Chr (203) 43 (68.3
EU (51) vs SR (63) 21 (41.2
NOTE. Two-tailed P values were calculated for 2  2 contingency table
5% CI, 95% confidence interval; Chr, chronically infected HCV patien
Table 3. Multivariate Logistic Regression Analysis of the Inter
Spontaneous Resolvers and 234 Chronically Infected
SR, n (%) Chro
860-CC 62 (69.7) 10
2DL3:C1 homozygous 26 (29.2) 3
860CC2DL3:C1 homozygous 19 (21.3) 1
NOTE. The 3 variables included in this analysis were IL28B.rs12979
IL28B.rs12979860CC in combination with KIR2DL3:HLA-C group 1 ho
95% CI, 95% confidence interval; Chronic, chronically infected HCV patienndividuals. However, no synergy was found (synergy
actor  1.53 [95% CI: 0.44–5.37], Psynergy  .5). Thus,
these polymorphisms of the innate immune system
distinguish EU from both SR and chronically infected
individuals and operate independently to protect indi-
viduals against chronic HCV infection.
Discussion
HCV causes chronic infection in the majority of
exposed individuals, thus protection from HCV infection
is the exception rather than the norm. Individuals with
beneficial immune responses have traditionally been iden-
tified as anti-HCV positive, HCV RNA negative. More
recently, individuals who remain seronegative and avire-
mic despite high-risk behavior have also been shown to be
relatively protected against chronic infection. These indi-
viduals have detectable T-cell responses,12,13,22 a favorable
KIR2DL3:HLA-C genotype,10 and also a protective IL12
genotype.15,16 In this respect, they are indistinguishable
from conventional SR. However, our data show that pro-
tection in this subgroup of individuals is not associated
with the IL28B.rs12979860-CC genotype, which marks
them as distinct from SR. Indeed, they are the first sub-
group of individuals identified who have a favorable out-
come following HCV exposure who do not have an over-
representation of this genotype. This is unlikely to
represent a bias related to the ethnicity of our population
because all EU individuals were Caucasian, and the fre-
quency of the IL28B.rs12979860-C allele (63.5%, Supple-
mentary Table 2) is comparable with that of 67.4% re-
ported by Thomas et al in Americans of European
extraction and is also similar to the frequency found in
other European populations.6 Therefore, it seems that
IL28B distinguishes the population of SR from other
healthy and HCV exposed populations.
ously Resolving, 234 Chronically Infected, and 74 Exposed
LA-C1 Genotype
0-CC positive, n (%) P value OR (95% CI)
s 17 (54.8) .1 2.23 (0.736.84)
s 19 (73.1) .046 (Pc  .1) 0.28 (0.090.94)
s 85 (41.9) .0003 (Pc  .0009) 2.98 (1.645.43)
s 43 (68.3) .0046 (Pc  .013) 0.33 (0.150.70)
sing Fisher exact test, and the Bonferroni correction was applied (Pc).
OR, odds ratio.
ion Between Individual Protective Factors in 89
dividuals
, n (%) P value OR 95% CI
3.6) .001 2.99 1.645.43
3.2) .04 2.94 1.068.20
.3) .1 0.75 0.212.67
CC (860-CC), KIR2DL3:HLA-C group 1 homozygosity (2DL3-C1), and
zygosity (860-CC2DL3-C1).ane
:H
86
) v
) v
) v
) v
s uact
In
nic
2 (4
1 (1
7 (7
860
mots; OR, odds ratio.
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324 KNAPP ET AL GASTROENTEROLOGY Vol. 141, No. 1Overall, given our understanding of the protective na-
ture of the rs12979860-CC genotype, it may be that this
enotype fails to deliver protection against acute HCV
nfection. One alternative explanation could be that the
s12979860TT genotype is protective against acute HCV
nfection. Potentially, this genotype could be associated
ith a weaker antibody response and a bias toward both
nnate and adaptive cell mediated immunity. Interest-
ngly, the rs12979860-TT genotype was over-represented in
ur EU cohort as compared with both SR and chronically
nfected individuals, consistent with a role in skewing the
mmune response away from antibody production. This
ifference is unlikely to be related to a population bias
ecause the trend was present when Caucasian individuals
lone were considered, and, also, the overall T allele fre-
quency was similar between EU and chronically infected
individuals.
Within the spontaneously resolving group are 2 distinct
populations: those resolving HCV via an IL28B-associated
mechanism and those with a protective KIR:HLA combi-
nation. We found that the combination of KIR2DL3:
HLA-C1 and IL28B.rs12979860-CC homozygosity did not
provide any additional protection above that due to each
genetic factor in isolation as determined both by logistic
regression and calculation of a synergy factor. This indi-
cates that they function as independent genetic protective
factors and do not have a synergistic interaction. The
calculation of a synergy factor allows separation of a
true synergistic interaction from an apparent one, that is,
one that is due to the expected increase in OR caused by
combining 2 protective factors.21 This analysis also com-
lements that performed by logistic regression, which
emonstrated that the combination of the 2 protective
actors had no advantage over that due to each factor in
solation. Additionally, the synergy factor is designed to
e robust for small samples sizes, even when individual
ells are zero.21 Thus, overall, the absence of a synergistic
nteraction between these factors is consistent with the
bservation that KIR:HLA, but not IL28B, is protective in
the EU cohort.
Both KIR2DL3:HLA-C1 and IL28B have predominantly
innate immune functions. KIR2DL3-positive NK cells are
activated in the acute phase of HCV infection, and we
have shown that KIR2DL3-positive NK cells from individ-
uals who resolve HCV have higher levels of degranulation
than healthy controls, but those from individuals who
become chronically infected do not.23 Thus, KIR2DL3 pro-
ection operates at the level of the NK cell. At present, the
echanism of action of IL28B in resolving HCV infection,
ither spontaneously or with treatment, is not clear. Al-
hough, as a type III interferon that shares signaling
athways with type I interferons,24 it most likely protects
ia a direct mechanism on the hepatocyte, possibly inhib-
ting HCV replication like the related molecule IFN-125
or rendering cells less susceptible to infection.26 Addition-
ally, IFN-2 does not appear to directly affect NK cells.27
Therefore, there is a biologic rationale for the separation
of these 2 genetic effects.One model for resistance to, or resolution of, HCV
infection is that possession of multiple independent pro-
tective factors may synergize to provide protection against
chronic infection so that individuals with more protective
factors have a greater chance of resolution of HCV infec-
tion. Our data do not support this hypothesis. Instead, we
propose that KIR:HLA and IL28B define 2 genetically dis-
tinct subpopulations of individuals who are relatively
protected against chronic HCV infection. Future genetic
studies of resolution of HCV infection should stratify for
these genotypes to take this heterogeneity into account.
Supplementary Material
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at doi:
10.1053/j.gastro.2011.04.005.
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325.e1 KNAPP ET AL GASTROENTEROLOGY Vol. 141, No. 1Supplementary Table 1. Frequency and Comparisons of the
Spontaneous Resolvers, and 234 C
rs12979860-T 2N (%)
U vs SR 54 (36.5) vs 32 (18.0)
U vs chronic 54 (36.5) vs 150 (32.1)
R vs chronic 32 (18.0) vs 150 (32.1)
OTE. Two-tailed P values were calculated for 2  2 contingency tabl
5% CI, 95% confidence interval; chronic, chronically infected HCV pSupplementary Table 2. Frequency and Comparisons of the IL28B.rs12979860-C Alleles in 74 Exposed Uninfected, 89
Spontaneous Resolvers, and 234 Chronically Infected HCV Patients
rs12979860-C 2N (%) P value (Pc) OR (95% CI)
EU vs SR 94 (63.5) vs 146 (82.0) .0002 (.0006) 0.38 (0.230.63)
EU vs chronic 94 (63.5) vs 318 (67.9) .1 0.82 (0.561.21)
SR vs chronic 146 (82.0) vs 318 (67.9) .0004 (.0012) 2.15 (1.403.31)
OTE. Two-tailed P values were calculated for 2  2 contingency tables using Fisher exact test, and the Bonferroni correction was applied (P ).IL28B.rs12979860-T Alleles in 74 Exposed Uninfected, 89
hronically Infected HCV Patients
P value (Pc) OR (95% CI)
.0002 (0.0006) 2.62 (1.584.36)
.1 1.22 (0.831.79)
.0004 (.0012) 0.46 (0.300.71)
es using Fisher exact test, and the Bonferroni correction was applied (P ).c
5% CI, 95% confidence interval; chronic, chronically infected HCV patients; OR, odds ratio.
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July 2011 IL28B IN EXPOSED UNINFECTED INDIVIDUALS 325.e2Supplementary Table 3. Comparison of the IL28B.rs12979860-CC, -CT, and -TT Genotypes in Caucasian Individuals
Genotypes EU, n (%) SR, n (%) Chr, n (%) EU vs SR EU vs Chr SR vs Chr
CC 31 (41.9) 60 (69.0) 93 (42.9) P  .0008 (Pc  .002)
OR  0.32
95% CI: 0.170.62
P  .1 P  .0001 (Pc  .0002)
OR  2.96
95% CI: 1.755.02
CT 32 (43.2) 22 (25.3) 106 (48.8) P  .019 (Pc  .06)
OR  2.25
95% CI: 1.164.39
P  .1 P  .0002 (Pc  .0006)
OR  0.35
95% CI  0.200.62
TT 11 (14.9) 5 (5.7) 18 (8.3) P  .07 (Pc  .2)
OR  2.86
95% CI: 0.058.67
P  .1 P  .1
NOTE. Includes 74 exposed uninfected, 87 spontaneous resolvers, and 217 chronically infected Caucasian individuals. Two-tailed P values were
calculated for 2  2 contingency tables using Fisher exact test, and the Bonferroni correction was applied (P ).c
5% CI, 95% confidence interval; Chr, chronically infected HCV patients; 2N, number of alleles; OR, odds ratio.Supplementary Table 4. Frequency of KIR2DL3:HLA-C1 Homozygosity in the Whole Cohort
KIR2DL3:C1 homozygosity, n (%) P value (Pc) OR (95% CI)
U vs SR 23 (31.1) vs 26 (29.2) .86 0.91 (0.471.79)
U vs chronic 23 (31.1) vs 31 (13.3) .0008 (.002) 2.95 (1.595.49)
SR vs chronic 26 (29.2) vs 31 (13.3) .002 (.005) 2.70 (1.494.89)
NOTE. Two-tailed P values were calculated for 2  2 contingency tables using Fisher exact test, and the Bonferroni correction was applied (P ).c
5% CI, 95% confidence interval; chronic, chronically infected HCV patients; OR, odds ratio.
